Retrieve available abstracts of 400 articles: HTML format
Single Articles
April 2025
CHOUAID C, Bosquet L, Knott C, Li Z, et al Real-world frontline treatments in patients with advanced non-small-cell lung
cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted
comparisons versus amivantamab plus chemotherapy from the PAPILLON study.
Lung Cancer. 2025;203:108548. PubMedAbstract available
BARSOUK A, Elghawy O, Watts A, Reed-Guy L, et al Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic
non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival
analysis.
Lung Cancer. 2025;203:108551. PubMedAbstract available
SHIRAISHI Y, Shimose T, Tobino K, Toi Y, et al Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for
advanced nonsquamous non-small cell lung cancer with impaired renal function: A
multicenter, single-arm phase 2 trial (RESTART, LOGiK 2002).
Lung Cancer. 2025;203:108543. PubMedAbstract available
VAES RDW, Cortiula F, Lyu S, Hiltermann TJN, et al Chemoradiotherapy efficacy in patients with stage III non-small cell lung cancer
(NSCLC): A prognostic clinical and biomarker-based model.
Lung Cancer. 2025;203:108541. PubMedAbstract available
PAN Y, Gu Q Efficacy and safety of targeted therapy combined with anti-angiogenesis treatment
in brain metastases of non-small cell lung cancer: a systematic review and
meta-analysis.
Lung Cancer. 2025;203:108532. PubMedAbstract available
SARKAR S, Choa E, Manzo LL, Richman I, et al Predictors and Uptake of Lung Cancer Screening in the US: An Integrative
Literature Review.
Lung Cancer. 2025;203:108529. PubMedAbstract available
WU Q, Li Q, Qin Y A cost-effectiveness analysis of amivantamab plus lazertinib versus osimertinib
in the treatment of US and Chinese patients with EGFR-mutated advanced non-small
cell lung cancer.
Lung Cancer. 2025;203:108533. PubMedAbstract available
AVANCINI A, Giaj-Levra N, Minuti G, Pasqualini G, et al Current diagnostic and therapeutical approaches to bone metastases in patients
with non-small cell lung cancer: A cross-sectional study.
Lung Cancer. 2025;203:108531. PubMedAbstract available
ROSENLUND L, Guldbrandsen K, Ahlborn LB, Bloch M, et al ctDNA can detect minimal residual disease in curative treated non-small cell lung
cancer patients using a tumor agnostic approach.
Lung Cancer. 2025;203:108528. PubMedAbstract available
AN Z, Ning Y, Mei J, Yang C, et al Evaluating the prognostic impact of EGFR mutation on adjuvant chemotherapy
efficacy in grade 3 stage IB lung adenocarcinoma.
Lung Cancer. 2025;202:108507. PubMedAbstract available
TAKAMOCHI K, Suzuki K, Okada M, Niho S, et al CRES(3)T: A single-arm confirmatory trial of S-1 plus cisplatin with concurrent
radical-dose radiotherapy followed by surgery for superior sulcus tumors.
Lung Cancer. 2025;202:108506. PubMedAbstract available
FAN M, Yan W, Zhuo M, Yu R, et al Feasibility and safety of perioperative entrectinib in a patient with
ROS1-positive locally advanced NSCLC: A case report.
Lung Cancer. 2025;202:108501. PubMedAbstract available
MESSEKHER M, Fuchs F, Badr M, Pujol JL, et al Gefitinib for EGFR mutated lung adenocarcinoma during pregnancy: A case report
with 5-Year Follow-Up.
Lung Cancer. 2025;202:108456. PubMedAbstract available
AHUJA G, Iyer A, Harwood R, Balata H, et al Pathological & radiological variables in the diagnosis of bronchopulmonary
carcinoids (BPCs) with a focus on Antigen Kiel 67 (Ki-67) proliferation index.
Lung Cancer. 2025;202:108493. PubMedAbstract available
TORASAWA M, Yoshida T, Shiraishi K, Yagishita S, et al Implications of EGFR expression on EGFR signaling dependency and adaptive
immunity against EGFR-mutated lung adenocarcinoma.
Lung Cancer. 2025;202:108494. PubMedAbstract available
LAVEN IEWG, Franssen AJPM, Gronenschild MHM, Heineman DJ, et al National clinical practice patterns of uniportal video-assisted thoracoscopic
anatomical lung resections: nationwide population-based data from a clinical
audit registry.
Lung Cancer. 2025;202:108481. PubMedAbstract available
GARASSINO MC, He Y, Ahn MJ, Orlov SV, et al Osimertinib long-term tolerability in patients with EGFRm NSCLC enrolled in the
AURA program or FLAURA study.
Lung Cancer. 2025;202:108417. PubMedAbstract available
KAWAKITA N, Takehara E, Takeuchi T, Fujimoto K, et al Advantages of a larger working channel diameter of ultrathin bronchoscope in
cone-beam computed tomography-guided transbronchial biopsy for diagnosing
peripheral lung lesions.
Lung Cancer. 2025;202:108483. PubMedAbstract available
SOO RA, Vervita K, Fruh M, Cho BC, et al A randomised non-comparative phase II study of atezolizumab, bevacizumab and
chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19
ABC-lung trial.
Lung Cancer. 2025;202:108454. PubMedAbstract available
March 2025
LINDBERG S, Grozman V, Karlsson K, Onjukka E, et al Stereotactic body radiation therapy (SBRT) of centrally located medically
inoperable early-stage non-small cell lung cancer (T1-T3N0M0) - A subgroup
analysis of the expanded HILUS study.
Lung Cancer. 2025;203:108527. PubMedAbstract available
LIU SV, Dziadziuszko R, Viteri S, Cappuzzo F, et al ARTEMIA phase 3 study: A randomized, open-label trial comparing the efficacy and
safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic
non-small cell lung cancer and secondary resistance to immune checkpoint
inhibitors.
Lung Cancer. 2025;203:108516. PubMed
ADDO S, Lycan T, Soto-Pantoja DR, Tsai YT, et al Randomized phase 2 trial of pembrolizumab alone or in combination with low dose
chemotherapy for patients with non-small cell lung cancer and poor performance
status.
Lung Cancer. 2025;203:108513. PubMedAbstract available
NARGUND RS, Ishizawa S, Eghbalizarch M, Yeh P, et al Natural history models for lung Cancer: A scoping review.
Lung Cancer. 2025;203:108495. PubMedAbstract available
ISAKA M, Notsu A, Kojima H, Konno H, et al Comparative validation of nodal classifications in resected non-small cell lung
cancer based on the anatomical location and number of involved stations.
Lung Cancer. 2025;203:108511. PubMedAbstract available
KESKIN O Beyond the Staging: Critical Insights into the Ninth TNM Edition for Lung Cancer.
Lung Cancer. 2025;203:108502. PubMed
TRIWIYANTO T, Alit Pawana I, Luthfiyah S Commentary on: Identification of key gene signatures for predicting
chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using
machine learning.
Lung Cancer. 2025;202:108512. PubMed
CHEN H, Cai W, Han Y, Zhao Y, et al Associations between carbohydrate quality and the survival of, and life
expectancy with lung cancer patient: A prospective cohort study.
Lung Cancer. 2025;203:108508. PubMedAbstract available
BOUSEMA JE, Spaans LN, Dijkgraaf MGW, van der Heijden EHFM, et al Two-year survival and disease recurrence after endosonography with or without
confirmatory mediastinoscopy for resectable lung cancer (a short communication of
the MEDIASTrial follow-up).
Lung Cancer. 2025;202:108462. PubMedAbstract available
HEMMINKI K, Zitricky F, Sundquist K, Sundquist J, et al Lung cancer risk between maternal and paternal half-siblings points to main
environmental causation and targets for prevention.
Lung Cancer. 2025;202:108500. PubMedAbstract available
GOTO Y, Watanabe S, Yanagimura N, Arita M, et al The diagnostic value of comprehensive next-generation sequencing for genetic
mutations in suspected lung cancer cases with negative pathological cytology.
Lung Cancer. 2025;202:108505. PubMedAbstract available
GOBBINI E, Diallo MH, Pasquier D, Schneider S, et al Clinical characteristics and management of long survivors in extensive stage
small cell lung cancer.
Lung Cancer. 2025;202:108499. PubMedAbstract available
JABER G, Raffoul C, Diab T, Sinno S, et al ALK-EML4 Fusion in Small Cell Lung Cancer: Clinical and Molecular Insights From a
Rare Case.
Lung Cancer. 2025;202:108497. PubMedAbstract available
VAN DER WEL JWT, de Langen AJ Novel strategies for rare oncogenic drivers in non-small-cell lung cancer: An
update from the 2024 Annual ESMO meeting.
Lung Cancer. 2025 Mar 14:108490. doi: 10.1016/j.lungcan.2025.108490. PubMedAbstract available
NAVEED F, Khan S, Khan A, Arshad F, et al Letter: Alectinib combined with cobimetinib in ALK-rearranged lung cancer: A
phase IB study.
Lung Cancer. 2025;202:108489. PubMed
NOUSIAS O, Mandell JD, Anderson KS, Townsend JP, et al Precision projections of the delay of resistance mutations in non-small cell lung
cancer via suppression of APOBEC.
Lung Cancer. 2025;202:108487. PubMedAbstract available
SETO T, Nakane S, Ji L, Ueda Y, et al Real-world safety and effectiveness of entrectinib in Japanese patients with ROS1
gene fusion-positive, unresectable, advanced/recurrent non-small cell lung
cancer: Post-marketing surveillance.
Lung Cancer. 2025;203:108478. PubMedAbstract available
VERKOULEN KCHA, Laven IEWG, Daemen JHT, Franssen AJPM, et al From data to prediction: Digital chest drain insights into postoperative recovery
after lung cancer surgery.
Lung Cancer. 2025;202:108486. PubMedAbstract available
CHO BC, Johnson M, Bar J, Schaefer E, et al A phase 1b study of cofetuzumab pelidotin monotherapy in patients with
PTK7-expressing recurrent non-small cell lung cancer.
Lung Cancer. 2025;202:108492. PubMedAbstract available
COOKE S, Nelson D, Argin AA, Laparidou D, et al Identifying and exploring patient engagement interventions for people diagnosed
with lung cancer: A rapid systematic review.
Lung Cancer. 2025;202:108484. PubMedAbstract available
VINAS F, Goussault H, Boyer L, Bussac GR, et al Evaluation of teleguided high-intensity exercise rehabilitation at home before
lung-cancer surgery (PREPACHIR Study).
Lung Cancer. 2025;202:108480. PubMedAbstract available
FROST MG, Jensen KJ, Jimenez-Solem E, Qvortrup C, et al Sex disparities in advanced non-small cell lung cancer survival: A Danish
nationwide study.
Lung Cancer. 2025;202:108485. PubMedAbstract available
GRIDELLI C, Attili I, Bennati C, Bironzo P, et al Immunotherapy in advanced non-small cell lung cancer: What to do for the
'Invisible' patients after IPSOS trial results?
Lung Cancer. 2025;202:108482. PubMedAbstract available
IGLESIAS MARTINEZ B, Insa A, Cervera Ygual G, Gascon F, et al Use of immune checkpoint inhibitors in patients with lung cancer and multiple
sclerosis.
Lung Cancer. 2025;202:108464. PubMedAbstract available
UEHARA Y, Izumi H, Kobayashi IS, Matsumoto S, et al Efficacy of EGFR tyrosine kinase inhibitors in patients with non-small cell lung
cancer with EGFR exon 19 insertions: clinical-genomic, preclinical analysis
through LC-SCRUM-Asia (multi-institutional genomic screening registry).
Lung Cancer. 2025;202:108479. PubMedAbstract available
GROS L, Yip R, Flores RM, Zhang J, et al Prospective cohort study of Suture-Line recurrence and clinical outcomes in stage
1A Non-Small cell lung cancer.
Lung Cancer. 2025;202:108465. PubMedAbstract available
ZHANG M, Deng C, Fu F, Li Y, et al Site-specific follow-up strategy for surgically resected patients with NSCLC
based on ten-year follow-up data.
Lung Cancer. 2025;201:108451. PubMedAbstract available
MORIMOTO K, Yamada T, Furuya N, Tanaka H, et al Exploration of clinical Biomarkers for guiding treatment selection between
chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin,
and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The
SPIRAL-STEP study.
Lung Cancer. 2025;201:108447. PubMedAbstract available
CHOI W, Lee W, Kim Y, Lee SJ, et al Immune landscape and novel therapeutic targets of epidermal growth factor
receptor and anaplastic lymphoma kinase wild type never-smoker lung
adenocarcinoma.
Lung Cancer. 2025;201:108448. PubMedAbstract available
SUBRAMANIAN J, Gregg J, Berktas M, Li J, et al EGFR testing practices, treatment choice and clinical outcomes in advanced NSCLC
in a real-world setting: A retrospective analysis of a US-based electronic health
records database.
Lung Cancer. 2025;201:108412. PubMedAbstract available
CAMIDGE DR, Sugawara S, Kondo M, Kim HR, et al Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+
NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trials.
Lung Cancer. 2025;201:108424. PubMedAbstract available
YAO Z, Qiu T, Li C, Kong W, et al Primary pulmonary adenoid cystic carcinoma: A study of clinicopathological
features and molecular alterations in twenty-one cases.
Lung Cancer. 2025;201:108414. PubMedAbstract available
February 2025
SAW SPL, Takano A, Zhou S, Hlaing NO, et al EGFR mutation status affects intra-tumoural heterogeneity of PD-L1 expression but
not agreement between assays in resectable non-small cell lung cancer.
Lung Cancer. 2025;202:108463. PubMedAbstract available
YANG YH, Kim HE, Park BJ, Lee JG, et al Patterns and preoperative risk factors of occult lymph node metastasis in
clinical stage I lung cancer.
Lung Cancer. 2025;202:108461. PubMedAbstract available
MA Z, Fu F, Zhang Y, Chen H, et al Long-term outcomes of neoadjuvant gefitinib in resectable stage II-IIIA non-small
cell lung cancer: A phase II, prospective cohort study.
Lung Cancer. 2025;201:108457. PubMedAbstract available
BAUMAN JR, Liu G, Preeshagul I, Liu SV, et al Corrigendum to "Real-world treatment sequencing and effectiveness of second- and
third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced
non-small cell lung cancer" [Lung Cancer 195 (2024) 107919].
Lung Cancer. 2025 Feb 22:108441. doi: 10.1016/j.lungcan.2025.108441. PubMed
JOHNSON M, Younan D, Kent ST, Frias MM, et al Corrigendum to "Real-world comparative effectiveness of sotorasib versus
docetaxel in second line and beyond among patients with advanced non-small cell
lung cancer (NSCLC)" [Lung Cancer 197 (2024) 107960].
Lung Cancer. 2025 Feb 20:108440. doi: 10.1016/j.lungcan.2025.108440. PubMed
LEE K, Kim TH, Yong Lee S, Lee YG, et al Delayed central nervous system progression with atezolizumab plus chemotherapy in
extensive-stage small-cell lung cancer (LU23-15).
Lung Cancer. 2025;201:108455. PubMedAbstract available
GIRARD N, Han JY, Soo RA, Wang K, et al Comparative effectiveness and safety of tislelizumab versus other anti-PD-(L)1
agents in first- and subsequent lines in locally advanced or metastatic non-small
cell lung cancer: Systematic literature review and network meta-analysis.
Lung Cancer. 2025;201:108450. PubMedAbstract available
SATOH H, Okuma Y, Shinno Y, Masuda K, et al Evolving treatments and prognosis in Stage IV non-small cell lung cancer: 20
years of progress of novel therapies.
Lung Cancer. 2025;202:108453. PubMedAbstract available
SANKAR K, Mercer J, Jaeger EB, Godden J, et al DNA damage repair gene alterations influence the tumor immune microenvironment in
advanced non-small cell lung cancer.
Lung Cancer. 2025;201:108444. PubMedAbstract available
SHAHNAM A, Davis A, Brown LJ, Sullivan I, et al Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C
and KRAS G12D mutations.
Lung Cancer. 2025;201:108421. PubMedAbstract available
AHN B, Kim D, Ji W, Chun SM, et al Clinicopathologic and genomic analyses of SMARCA4-mutated non-small cell lung
carcinoma implicate the needs for tailored treatment strategies.
Lung Cancer. 2025;201:108445. PubMedAbstract available
HUANG L, Petersen RH Tumour spread through air spaces is a determiner for treatment of clinical stage
I non-small cell lung Cancer: Thoracoscopic segmentectomy vs lobectomy.
Lung Cancer. 2025;201:108438. PubMedAbstract available
BOSCH-BARRERA J, Estevez-Garcia P, Martin-Martorell P, Sabatier R, et al ENDOLUNG trial, part II. A phase II study of the Akt/mTOR inhibitor and autophagy
inducer ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in
patients with squamous non-small cell lung cancer.
Lung Cancer. 2025;201:108105. PubMedAbstract available
AKAMATSU H, Nishikawa T, Takeda Y, Misumi T, et al Longitudinal recurrence risk of adjuvant cytotoxic chemotherapy and gefitnib in
resected lung cancer: A combined analysis of phase III studies.
Lung Cancer. 2025;201:108437. PubMedAbstract available
HE Q, Jiang L, Xu Y, Wang M, et al Evaluating the safety of antibody-drug conjugates in lung cancer: A systematic
review and meta-analysis.
Lung Cancer. 2025;201:108425. PubMedAbstract available
ATASEVER F, Sokucu SN, Satici C Letter to the editor concerning "Comparison of radiotherapy versus surgical
resection following neoadjuvant chemoimmunotherapy in potentially resectable
stage III non-small-cell lung cancer: A propensity score matching analysis".
Lung Cancer. 2025;201:108423. PubMed
FICARRA S, Kang DW, Wilson RL, Gonzalo-Encabo P, et al Exercise medicine for individuals diagnosed with Lung Cancer: A systematic review
and meta-analysis of health outcomes.
Lung Cancer. 2025;201:108413. PubMedAbstract available
UPRETY D, Abrahami D, Marcum ZA, Li B, et al Brain metastases and mortality in patients with ALK + metastatic non-small cell
lung cancer treated with second-generation ALK tyrosine kinase inhibitors as
first-line targeted therapies: An observational cohort study.
Lung Cancer. 2025;201:108436. PubMedAbstract available
TAMBO Y, Sone T, Nishi K, Shibata K, et al Five-year efficacy and safety of pembrolizumab as first-line treatment in
patients with non-small cell lung cancer with PD-L1 tumor proportion score >/=50 %:
A multicenter observational study.
Lung Cancer. 2025;201:108422. PubMedAbstract available
SUMI T, Ishigooka T, Matsuura K, Ikeda T, et al Dual onsets of small cell lung cancer with contrasting neuroendocrine features
and immune microenvironments: A case report.
Lung Cancer. 2025;201:108420. PubMedAbstract available
WANG Y, Fujita RA, Fujisawa N, Laskin J, et al Mitigation of decline with virtual exercise with lung cancer (MoVE with lung
cancer) - A promising approach to enhance physiological strength, improve body
composition, and build upon current evidence.
Lung Cancer. 2025;201:108418. PubMedAbstract available
IKEDA S, Ogura T, Miyaoka E, Sekine I, et al Survival benefit and potential markers of chemotherapy for elderly and poor
performance status patients with advanced non-small cell lung cancer: Results
from the Japanese Joint Committee of lung cancer registry database.
Lung Cancer. 2025;200:108102. PubMedAbstract available
REUSS JE, Zaemes J, Gandhi N, Walker P, et al Comprehensive molecular profiling of squamous non-small cell lung cancer reveals
high incidence of actionable genomic alterations among patients with no history
of smoking.
Lung Cancer. 2025;200:108101. PubMedAbstract available
HATA T, Yamada T, Goto Y, Amano A, et al Comparative analysis of first-line treatment in NSCLC including unresectable
stage III (IIIB/IIIC) and stage IV with low PD-L1 expression: Clinical trial
eligible versus ineligible patients.
Lung Cancer. 2025;200:108104. PubMedAbstract available
NARITA D, Hishinuma E, Ebina-Shibuya R, Miyauchi E, et al Histological and genetic features and therapeutic responses of lung cancers
explored via the global analysis of their metabolome profile.
Lung Cancer. 2025;200:108082. PubMedAbstract available
GOMEZ-RANDULFE I, Scanlon LA, Carter M, Moliner L, et al First-line osimertinib compared to earlier generation TKIs in advanced
EGFR-mutant NSCLC: A real-world survival analysis.
Lung Cancer. 2025;200:108084. PubMedAbstract available
January 2025
DOBKIN J, Stanifer BP, Salvatore M, Eckhardt CM, et al Evaluating lung cancer risk factors in adults with interstitial lung disease.
Lung Cancer. 2025;201:108416. PubMedAbstract available
NISHI T, Morita A, Hara N, Makimoto G, et al Efficacy of amivantamab, a bi-specific antibody targeting EGFR and MET, in
ALK-rearranged non-small-cell lung cancer cell lines.
Lung Cancer. 2025;201:108415. PubMedAbstract available
LIU T, He J, Wang Y, Yang Y, et al Health-related quality of life and symptoms in patients with previously
untreated, locally advanced or metastatic non-squamous non-small cell lung cancer
treated with sintilimab or placebo plus pemetrexed and platinum (ORIENT-11): A
randomized, double
Lung Cancer. 2025;200:108108. PubMedAbstract available
HOFMAN P, Ourailidis I, Romanovsky E, Ilie M, et al Artificial intelligence for diagnosis and predictive biomarkers in Non-Small cell
lung cancer Patients: New promises but also new hurdles for the pathologist.
Lung Cancer. 2025;200:108110. PubMedAbstract available
HOFMAN P, Christopoulos P, D'Haene N, Gosney J, et al Proposal of real-world solutions for the implementation of predictive biomarker
testing in patients with operable non-small cell lung cancer.
Lung Cancer. 2025;201:108107. PubMedAbstract available
AHMAD SQ, Pesola F, Crosbie PAJ, Gabe R, et al Adherence to community-based lung cancer screening in the Yorkshire Lung
Screening Trial.
Lung Cancer. 2025;200:108086. PubMedAbstract available
LEE KH, Lee JS, Sugawara S, Kang JH, et al First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced
nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3
randomized TASUKI-52 trial.
Lung Cancer. 2025;201:108109. PubMedAbstract available
MUNOZ OM, Delgado Leon BD, Selles EG, Enguix-Riego MV, et al Association of single nucleotide polymorphisms rs7459185 of the HSPbeta1 gene and
the risk of hematological toxicity in lung cancer.
Lung Cancer. 2025;200:108103. PubMedAbstract available
GRIDELLI C, Mok T, Janne P, Passaro A, et al Debate on first-line treatment strategies in advanced non-small cell lung cancer
with EGFR mutation: An expert panel meeting by the Italian Association of
Thoracic Oncology (AIOT).
Lung Cancer. 2025;201:108100. PubMedAbstract available
FUJII K, Ueki M, Morishita M, Ikushima H, et al Clinical utility of comprehensive genomic profiling in non-small cell lung
cancer: An analysis of a nation-wide database.
Lung Cancer. 2025;200:108099. PubMedAbstract available
MULLALLY WJ, O'Leary CG, O'Byrne KJ Rearranged during transfection (RET) lung cancer - Update on targeted therapies.
Lung Cancer. 2025;200:108083. PubMedAbstract available
DECOSTER L, Camidge DR, Fletcher JA, Addeo A, et al Targeted therapy for older patients with an oncogene driven non-small cell lung
cancer: Recommendations from a SIOG expert group.
Lung Cancer. 2025;200:108087. PubMedAbstract available
WU L, Tian JY, Li MJ, Jiang F, et al Validation of the 9th edition of the TNM staging system for limited-stage small
cell lung cancer after Resection: A multicenter study.
Lung Cancer. 2025;200:108085. PubMedAbstract available
TESEMA GA, Stirling RG, Wah W, Tessema ZT, et al Geographic variation in delay to surgical treatment among non-small cell lung
cancer patients.
Lung Cancer. 2025;199:108077. PubMedAbstract available
LI Y, Law J, Le LW, Li JJN, et al Assessing the feasibility and external validity of natural language
processing-extracted data for advanced lung cancer patients.
Lung Cancer. 2025;199:108080. PubMedAbstract available
WU Y, Tang Y, Huang W, Zhu C, et al Improving the screening ability of neuron-specific enolase on small cell lung
cancer.
Lung Cancer. 2025;199:108078. PubMedAbstract available
FUJIMOTO D, Shibaki R, Kimura K, Haratani K, et al Identification of key gene signatures for predicting chemo-immunotherapy efficacy
in extensive-stage small-cell lung cancer using machine learning.
Lung Cancer. 2025;199:108079. PubMedAbstract available
SAW SPL, Zhong WZ, Fu R, Li MSC, et al Asian Thoracic Oncology Research Group expert consensus statement on the
peri-operative management of non-small cell lung cancer.
Lung Cancer. 2025;200:108076. PubMedAbstract available
NANAMI H, Matsumoto Y, Furuse H, Tanaka M, et al Efficacy of cryobiopsy during medical thoracoscopy for diagnosing malignant
pleural mesothelioma.
Lung Cancer. 2025;199:108074. PubMedAbstract available
THUNNISSEN E, Blaauwgeers H, Filipello F, Lissenberg-Witte B, et al A reproducibility study on invasion in small pulmonary adenocarcinoma according
to the WHO and a modified classification, supported by biomarkers.
Lung Cancer. 2025;199:108060. PubMedAbstract available
TSUI DCC, Lee JK, Tambaoan CFB, Hughes J, et al Genomic analysis of comprehensive next generation sequencing data to explore the
criteria for MET amplification as an actionable biomarker in NSCLC.
Lung Cancer. 2025;199:108081. PubMedAbstract available
WU M, Zhou N, Guan M, Wang Y, et al Efficacy of immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma and
predictive potential of mutated TP53.
Lung Cancer. 2025;199:108068. PubMedAbstract available
SHIELDS MD, Minton KG, Tran M, Gunderman PR, et al Defining the needle in a haystack: A compendium of genomic, pathologic, and
clinical characteristics of rare pulmonary tumors.
Lung Cancer. 2025;199:108035. PubMedAbstract available
VOLMONEN KK, Ronty MJ, Sederholm A, Paajanen JI, et al Evaluating tumour budding could improve the new grading system for lung
adenocarcinoma.
Lung Cancer. 2025;199:108067. PubMedAbstract available
LEI M, Zhang X, Hu LN, Fu S, et al Perioperative immunotherapy plus chemotherapy versus chemotherapy alone for
patients with resectable pulmonary lymphoepithelioma-like carcinoma.
Lung Cancer. 2025;199:108057. PubMedAbstract available
DE GIGLIO A, De Biase D, Favorito V, Maloberti T, et al STK11 mutations correlate with poor prognosis for advanced NSCLC treated with
first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1,
and SMARCA4 status.
Lung Cancer. 2025;199:108058. PubMedAbstract available
HE L, Zhang B, Zhou C, Zhao Q, et al A combined model of circulating tumor DNA methylated SHOX2/SCT/HOXA7 and clinical
features facilitates the discrimination of malignant from benign pulmonary
nodules.
Lung Cancer. 2025;199:108064. PubMedAbstract available
December 2024
OGLIARI FR, Traverso A, Barbieri S, Montagna M, et al Exploring machine learning tools in a retrospective case-study of patients with
metastatic non-small cell lung cancer treated with first-line immunotherapy: A
feasibility single-centre experience.
Lung Cancer. 2024;199:108075. PubMedAbstract available
NAKAO M, Suzuki A, Ichinose J, Matsuura Y, et al Prognostic impact of the N2 subclassification and stage migration in the ninth
edition of the TNM classification in surgically resected lung cancer.
Lung Cancer. 2024;199:108073. PubMedAbstract available
AGUADO-BARRERA ME, Lopez-Pleguezuelos C, Gomez-Caamano A, Calvo-Crespo P, et al Professional-patient discrepancies in assessing lung cancer radiotherapy
symptoms: An international multicentre study.
Lung Cancer. 2024;199:108072. PubMedAbstract available
HARRIS RA, Stokes EA, Batchelor TJP, Internullo E, et al Optimum diagnostic pathway and pathologic confirmation rate of early stage lung
cancer: Results from the VIOLET randomised controlled trial.
Lung Cancer. 2024;199:108070. PubMedAbstract available
SZTANKOVICS D, Szalai F, Moldvai D, Danko T, et al Comparison of molecular subtype composition between independent sets of primary
and brain metastatic small cell lung carcinoma and matched samples.
Lung Cancer. 2024;199:108071. PubMedAbstract available
WELLER M, Le Rhun E, Tsamtsouri L, Dummer R, et al Immunotherapy or targeted therapy with or without stereotactic radiosurgery for
patients with brain metastases from melanoma or non-small cell lung cancer - The
ETOP 19-21 USZ-STRIKE study.
Lung Cancer. 2024;199:108069. PubMed
SUAZO-ZEPEDA E, Viddeleer AR, Maas WJ, Postmus D, et al CT-assessed sarcopenia and immune-related adverse events in patients with lung
cancer: A competing risk time-to-event analysis.
Lung Cancer. 2024;199:108054. PubMedAbstract available
ZERDES I, Kamali C, Johannsdottir B, Blasi M, et al A novel clinical brain prognostic index for KRAS-mutated lung cancer and brain
metastases (KRAS-BPI): Real-world evidence from two large European centers.
Lung Cancer. 2024;199:108065. PubMedAbstract available
MA Z, Liu Y, Bao Y, Wang M, et al Impact of locoregional recurrence versus distant metastasis on overall survival
in patients with Non-Small cell lung cancer after Surgery: A secondary analysis
of PORT-C RCT.
Lung Cancer. 2024;199:108063. PubMedAbstract available
DONG Y, Yang G, Yang Y, Zhang S, et al Dynamic characterization of circulating tumor DNA in HER2-altered advanced
non-small cell lung cancer treated with pyrotinib and apatinib: Exploratory
biomarker analysis from PATHER2 study.
Lung Cancer. 2024;200:108062. PubMedAbstract available
HOUDA I, Bahce I, Dickhoff C, Kroese TE, et al An international and multidisciplinary EORTC survey on resectability of stage III
non-small cell lung cancer.
Lung Cancer. 2024;199:108061. PubMedAbstract available
GELSOMINO F, Boni L, Tiseo M, Ricciardi S, et al An open-label, randomized phase III study of early switch maintenance vs delayed
second-line nivolumab in advanced stage squamous non-small cell lung cancer
(NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial
GOIRC 04-201
Lung Cancer. 2024;199:108059. PubMedAbstract available
SUGISAKA J, Fujimoto D, Tamiya M, Hata A, et al Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung
cancer according to key clinical trial eligibility: 3-year outcomes from a
prospective cohort study.
Lung Cancer. 2024;199:108056. PubMedAbstract available
URTECHO SB, Provenzano L, Spagnoletti A, Bottiglieri A, et al Decoding KRAS mutation in non-small cell lung cancer patients receiving
immunotherapy: A retrospective institutional comparison and literature review.
Lung Cancer. 2024;199:108051. PubMedAbstract available
WANG M, Xu Y, Huang WT, Su WC, et al Sunvozertinib monotherapy in EGFR tyrosine kinase inhibitor-resistant non-small
cell lung cancer with EGFR mutations.
Lung Cancer. 2024;199:108053. PubMedAbstract available
KARAYAMA M, Suda T, Yoh K, Usui K, et al Difference in efficacy of osimertinib between patients with EGFR-positive NSCLC
with postoperative recurrence and those with de novo unresectable disease: A
prospective, observational study.
Lung Cancer. 2024;198:108037. PubMedAbstract available
FERNANDEZ-BUSSY S, Funes-Ferrada R, Yu Lee-Mateus A, Vaca-Cartagena BF, et al Diagnostic performance of Shape-Sensing Robotic-Assisted bronchoscopy with mobile
Cone-Beam CT for cystic and cavitary pulmonary lesions.
Lung Cancer. 2024;198:108029. PubMedAbstract available
JOHN A, McMahon DJ, Chauhan D, Mullings S, et al Lorlatinib-associated weight gain and dyslipidaemia: A retrospective analysis and
implications for future care.
Lung Cancer. 2024;198:108034. PubMedAbstract available
AYOADE O, Canavan ME, Caturegli G, Boffa DJ, et al Brief Report: Should a prior cancer history be reevaluated as an exclusion for
clinical trial participation?
Lung Cancer. 2024;198:108032. PubMedAbstract available
HEIJBOER FWJ, Mulders TA, van Straten M, Moonen L, et al Radiological follow-up in patients with resected pulmonary carcinoids: Should we
reduce radiation exposure?
Lung Cancer. 2024;198:108030. PubMedAbstract available
VAN DER WEL JWT, Jebbink M, van den Broek D, Steinbusch LC, et al Combined analysis of circulating tumor DNA and tumor tissue to overcome
osimertinib resistance (OSIRIS); the second line osimertinib cohort.
Lung Cancer. 2024;198:107972. PubMedAbstract available
WANG L, Song B, Zhang Z, Bo B, et al Evaluating efficacy and safety of a novel registration-free CT-guided needle
biopsy navigation system (RC 120): A multicenter, prospective clinical trial.
Lung Cancer. 2024;198:108025. PubMedAbstract available
SANTARPIA M, Aliprandi M, Claudia Spagnolo C, Avan A, et al NOTCH and PTP4A3 alterations emerge as novel predictive biomarkers and potential
therapeutic targets in pleural mesothelioma.
Lung Cancer. 2024;198:108024. PubMedAbstract available
November 2024
SWALDUZ A, Beau-Faller M, Planchard D, Mazieres J, et al Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF
V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the
IFCT-2004 BLaDE cohort.
Lung Cancer. 2024;199:108038. PubMedAbstract available
AUCLIN E, Roulleaux Dugage M, Gorria T, Vauchier C, et al Validation of the Lung Immune Prognostic Index in patients with untreated
advanced non-small cell lung cancer: Post hoc analysis of the IMpower 130, 131
and 150 trials.
Lung Cancer. 2024;199:108039. PubMedAbstract available
PATIL T, Gao D, Watson A, Sakamoto M, et al The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon
progression in patients with metastatic non-small cell lung cancer harboring
sensitizing EGFR mutations.
Lung Cancer. 2024;199:108040. PubMedAbstract available
JUNG W, Cho IY, Jeon KH, Yeo Y, et al Addressing knowledge and attitude barriers to lung cancer screening: Development
and evaluation of web-based decision aid.
Lung Cancer. 2024;198:108031. PubMedAbstract available
ZENG H, Schagen SB, Hendriks LEL, Sanchez-Benavides G, et al Impact of HA-PCI on self-reported cognitive functioning and brain metastases in
small-cell lung cancer: Pooled findings of NCT01780675 and PREMER trials.
Lung Cancer. 2024;199:108036. PubMedAbstract available
YU Z, Zou J, Xu F The molecular subtypes of small cell lung cancer defined by key transcription
factors and their clinical significance.
Lung Cancer. 2024;198:108033. PubMedAbstract available
BAHADORI S, Hosseini M Use of commercial WAMs for monitoring individual with lung cancer. A systematic
review.
Lung Cancer. 2024;198:108026. PubMedAbstract available
OSATAPHAN S, Awidi M, Jan YJ, Gunturu K, et al Association between higher glucose levels and reduced survival in patients with
non-small cell lung cancer treated with immune checkpoint inhibitors.
Lung Cancer. 2024;198:108023. PubMedAbstract available
HORINOUCHI H, Murakami H, Harada H, Sobue T, et al Real-world status of multimodal treatment of Stage IIIA-N2 non-small cell lung
cancer in Japan: Results from the SOLUTION study, a non-interventional,
multicenter cohort study.
Lung Cancer. 2024;199:108027. PubMedAbstract available
KOSAKA N, Kataoka Y Letter regarding "The significance of inflammatory markers in prognosticating the
effectiveness and safety of immunotherapy in conjunction with chemotherapy during
the primary intervention of advanced non-small cell lung carcinoma".
Lung Cancer. 2024;198:108020. PubMed
YU Y, Fan Y, Dong X, Li J, et al Entrectinib versus crizotinib in Asian patients with ROS1-positive non-small cell
lung cancer: A matching-adjusted indirect comparison.
Lung Cancer. 2024;198:108018. PubMedAbstract available
LIU H, Hong Q, Zheng S, Zhang M, et al Effective treatment strategies and key factors influencing therapeutic efficacy
in advanced SMARCA4-deficient non-small cell lung cancer.
Lung Cancer. 2024;198:108022. PubMedAbstract available
AKAMATSU H, Koh Y, Nishio M, Goto Y, et al Comprehensive serum biomarker analysis reveals IL-8 changes as the only predictor
of the effectiveness of immune checkpoint inhibitors for patients with advanced
non-small cell lung cancer.
Lung Cancer. 2024;198:108017. PubMedAbstract available
ZHANG B, Bao H, Li Z, Chen J, et al Continuing immune checkpoint inhibitors after progression: Real-world patterns of
care and outcomes in second-line treatment for extensive-stage small-cell lung
cancer.
Lung Cancer. 2024;199:108021. PubMedAbstract available
DONG J, Bao H Comment on: Efficacy and safety of crizotinib in the treatment of advanced
non-small cell lung cancer with ROS1 gene fusion: A systematic literature review
and meta-analysis of real-world evidence.
Lung Cancer. 2024;201:108019. PubMed
BAUMAN JR, Liu G, Preeshagul I, Liu SV, et al Corrigendum to "Real-world treatment sequencing and effectiveness of second- and
third-generation ALK tyrosine kinase inhibitors for ALK -positive advanced
non-small cell lung cancer" [Lung Cancer 195 (2024) 107919].
Lung Cancer. 2024 Nov 1:108000. doi: 10.1016/j.lungcan.2024.108000. PubMed
TU X, Lu Z, Hei F, Zhang T, et al Putative mechanisms of primary resistance to EGFR-targeted therapies: A
retrospective study.
Lung Cancer. 2024;197:107998. PubMedAbstract available
HE X, Yang Z, Wu F, Liang Q, et al Confronting synchronous multiple primary lung cancers: Navigating the
intersection of challenges and opportunities.
Lung Cancer. 2024;197:107994. PubMedAbstract available
FILIPELLO F, Blaauwgeers H, Lissenberg-Witte B, Schonau A, et al Stereologic consequences of iatrogenic collapse: The morphology of adenocarcinoma
in situ overlaps with invasive patterns. Proposal for a necessary modified
classification of pulmonary adenocarcinomas.
Lung Cancer. 2024;197:107987. PubMedAbstract available
XU D, Liang SQ, Su M, Yang H, et al Crispr-mediated genome editing reveals a preponderance of non-oncogene addictions
as targetable vulnerabilities in pleural mesothelioma.
Lung Cancer. 2024;197:107986. PubMedAbstract available
ZWIERENGA F, Zhang L, Melcr J, Schuuring E, et al The prediction of treatment outcome in NSCLC patients harboring an EGFR exon 20
mutation using molecular modeling.
Lung Cancer. 2024;197:107973. PubMedAbstract available
TABE C, Fujita T, Taima K, Tanaka H, et al Highly sensitive and accurate detection of ALK-TKI resistance mutations by
oligoribonucleotide interference-PCR (ORNi-PCR)-based methods.
Lung Cancer. 2024;197:107969. PubMedAbstract available
SNIDER M, Salama JK, Boyer M Survival and recurrence rates following SBRT or surgery in medically operable
Stage I NSCLC.
Lung Cancer. 2024;197:107962. PubMedAbstract available
BRUNE MM, Savic Prince S, Vlajnic T, Chijioke O, et al MTAP as an emerging biomarker in thoracic malignancies.
Lung Cancer. 2024;197:107963. PubMedAbstract available
UCHIBORI A, Okada S, Shimomura M, Furuya T, et al Clinical impact of preoperative sarcopenia and immunonutritional impairment on
postoperative outcomes in non-small cell lung cancer surgery.
Lung Cancer. 2024;198:108004. PubMedAbstract available
DAGOGO-JACK I, Cooper AJ, Johnson BE, Gainor JF, et al Alectinib combined with cobimetinib in ALK-Rearranged lung Cancer: A phase IB
study.
Lung Cancer. 2024;199:108003. PubMedAbstract available
October 2024
VINCE M, Naqvi SMH, Pellini B, Verbosky M, et al Real-world comparison of the efficacy and safety of atezolizumab versus
durvalumab in extensive-stage small cell lung cancer.
Lung Cancer. 2024;198:107999. PubMedAbstract available
PISAPIA P, Russo A, De Luca C, Pepe F, et al The relevance of the reference range for EGFR testing in non-small cell lung
cancer patients.
Lung Cancer. 2024;198:108002. PubMedAbstract available
PANG J, Zhang Y, Wang X, Wu W, et al Clinical benefit evaluation of drug treatment regimens for advanced lung
cancer:based on ASCO-VF and ESMO-MCBS.
Lung Cancer. 2024;197:108001. PubMedAbstract available
CHAN YH, Yuen-Ting C, Sin CF, Ma ESK, et al Treatment with trimetazidine dihydrochloride and lung cancer survival:
Implications on metabolic re-programming.
Lung Cancer. 2024;197:107996. PubMedAbstract available
AY L, Steiner D, Fabikan H, Illini O, et al Neoadjuvant therapy in early-stage non-small cell lung cancer: A real-world
analysis.
Lung Cancer. 2024;198:107997. PubMedAbstract available
LEVY A, Berghmans T, Koller M, Fournier B, et al PRIMALung (EORTC-1901): PRophylactic cerebral irradiation (PCI) or active brain
MAgnetic resonance imaging (MRI) surveillance in small-cell lung cancer (SCLC)
patients.
Lung Cancer. 2024;198:107993. PubMedAbstract available
BERTOLACCINI L, Tralongo AC, Del Re M, Facchinetti F, et al Segmentectomy vs. Lobectomy in stage IA non-small cell lung cancer: A systematic
review and meta-analysis of perioperative and survival outcomes.
Lung Cancer. 2024;197:107990. PubMedAbstract available
TEIXIDOR-VILA E, Trallero J, Puigdemont M, Vidal-Vila A, et al Lung cancer survival trends and prognostic factors: A 26-year population-based
study in Girona Province, Spain.
Lung Cancer. 2024;197:107995. PubMedAbstract available
BAI Z, Cheng X, Ma T, Li G, et al CD8+ T cells infiltrating into tumors were controlled by immune status of
pulmonary lymph nodes and correlated with non-small cell lung cancer (NSCLC)
patients' prognosis treated with chemoimmunotherapy.
Lung Cancer. 2024;197:107991. PubMedAbstract available
KATO Y, Udagawa H, Matsumoto S, Izumi H, et al Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st
line treatment for patients with non-small cell lung cancer harboring HER2
mutations: Results from LC-SCRUM-Asia.
Lung Cancer. 2024;197:107992. PubMedAbstract available
HATA A, Katakami N, Takase N, Kibata K, et al Afatinib plus bevacizumab combination after osimertinib resistance in advanced
EGFR-mutant non-small cell lung cancer: Phase II ABCD-study.
Lung Cancer. 2024;197:107988. PubMedAbstract available
LI M, Soo RA Can therapeutic drug monitoring of lorlatinib help us design the right CROWN?
Lung Cancer. 2024;196:107965. PubMed
CHEN M, Huang Y, Jiang S, Ke C, et al Safety assessment of KRAS (G12C) inhibitors based on the FDA Adverse Event
Reporting System (FAERS) database: A real-world pharmacovigilance study.
Lung Cancer. 2024;196:107966. PubMedAbstract available
ABIA-TRUJILLO D, Funes-Ferrada R, Yu Lee-Mateus A, Barrios-Ruiz A, et al Cryobiopsy versus fine-needle aspiration for shape-sensing robotic-assisted
sampling of small lung nodules.
Lung Cancer. 2024;196:107967. PubMedAbstract available
SHIMODA IGAWA Y, Yoshida T, Makihara R, Torasawa M, et al Association between lorlatinib blood concentration and adverse events and
clinical impact of dose modification.
Lung Cancer. 2024;196:107954. PubMedAbstract available
WATERHOUSE DM, Rothschild S, Dooms C, Mennecier B, et al Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for
previously treated advanced NSCLC with KRAS G12C mutation.
Lung Cancer. 2024;196:107921. PubMedAbstract available
ZHU C What's behind thoracic surgery explosion in young patients under the age of 40 in
Wuhan after COVID-19 outbreak?
Lung Cancer. 2024;196:107937. PubMedAbstract available
YANG G, Chu Q Comment on: Effects of pregabalin combined with tramadol/paracetamol on acute
pain in patients with CT-guided puncture localization of pulmonary nodules.
Lung Cancer. 2024;196:107938. PubMed
September 2024
OU SH, Kilvert H, Candlish J, Lee B, et al Systematic review and network meta-analysis of lorlatinib with comparison to
other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as
first-line treatment for ALK-positive advanced non-smallcell lung cancer (NSCLC).
Lung Cancer. 2024;197:107968. PubMedAbstract available
CHEN R, Donlon TA, Morris BJ, Allsopp RC, et al Association of alcohol with lung cancer risk in men with different growth hormone
receptor genotypes.
Lung Cancer. 2024;198:107971. PubMedAbstract available
KANG DW, Park SK, Kang S, Lee EK, et al Cost-effectiveness of next-generation sequencing for advanced EGFR/ALK-negative
non-small cell lung cancer.
Lung Cancer. 2024;197:107970. PubMedAbstract available
PLANCHARD D, Wolf J, Solomon B, Sebastian M, et al A phase Ib study of the combination of naporafenib with rineterkib or trametinib
in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung
cancer.
Lung Cancer. 2024;197:107964. PubMedAbstract available
KAWAGUCHI K, Ogura T, Kaneda S, Watanabe T, et al A prospective multi-institutional study to verify the non-inferiority of
postoperative pain in robot-assisted thoracic surgery in comparison with
video-assisted thoracoscopic surgery for lung cancer: The Japanese RATS interest
group 01 (J-RATSIG 01).
Lung Cancer. 2024;196:107961. PubMedAbstract available
LI L, Liu N, Zhou T, Qin X, et al A biomarker exploration in small-cell lung cancer for brain metastases risk and
prophylactic cranial irradiation therapy efficacy.
Lung Cancer. 2024;196:107959. PubMedAbstract available
SHIBAKI R, Fujimoto D, Miyauchi E, Tsukita Y, et al Durvalumab with etoposide and carboplatin for patients with extensive-stage small
cell lung cancer and interstitial lung disease: A multicenter, open-label
prospective trial.
Lung Cancer. 2024;196:107958. PubMedAbstract available
JOHNSON M, Younan D, Kent ST, Mesa-Frias M, et al Real-world comparative effectiveness of sotorasib versus docetaxel in second line
and beyond among patients with advanced non-small cell lung cancer (NSCLC).
Lung Cancer. 2024;197:107960. PubMedAbstract available
ZHENG MZ, Yang ZQ, Cai SL, Zheng LT, et al Blood-brain barrier and blood-brain tumor barrier penetrating peptide-drug
conjugate as targeted therapy for the treatment of lung cancer brain metastasis.
Lung Cancer. 2024;196:107957. PubMedAbstract available
MARSHALL HM, Fong KM Lung cancer screening - Time for an update?
Lung Cancer. 2024;196:107956. PubMedAbstract available
MILDNER FO, Sykora MM, Hackl H, Amann A, et al Soluble PD-L1 shows no association to relapse and overall survival in early stage
non-small cell lung cancer (NSCLC).
Lung Cancer. 2024;196:107955. PubMedAbstract available
PRESLEY CJ, Tang J, Benedict J, Grogan M, et al Functional resilience and overall survival in adults treated for advanced
non-small-cell lung cancer.
Lung Cancer. 2024;196:107953. PubMedAbstract available
MARKS JA, Gandhi N, Halmos B, Marmarelis ME, et al Molecular profiling METex14+ non-small cell lung cancer (NSCLC): Impact of
histology.
Lung Cancer. 2024;196:107935. PubMedAbstract available
PEETERS S, Lau K, Stefanidis K, Yasufuku K, et al New diagnostic and nonsurgical local treatment modalities for early stage lung
cancer.
Lung Cancer. 2024;196:107952. PubMedAbstract available
MANSFIELD AS, Vivien Yin J, Bradbury P, Kwiatkowski DJ, et al Randomized trial of anetumab ravtansine and pembrolizumab compared to
pembrolizumab for mesothelioma.
Lung Cancer. 2024;195:107928. PubMedAbstract available
LIU KJ, Li HR, Tan QQ, Jiang T, et al Tumor immune microenvironment of NSCLC with EGFR exon 20 insertions may predict
efficacy of first-line ICI-combined regimen.
Lung Cancer. 2024;195:107933. PubMedAbstract available
NASO J, Desai A, Smith CJ, Ashara YP, et al Predictive value and molecular correlates of MYC immunohistochemistry and copy
number gain in non-small cell lung carcinomas treated with immunotherapy.
Lung Cancer. 2024;195:107927. PubMedAbstract available
WEI Y, Wu R, Yang S, Cao Y, et al MiR-137 mediated high expression of TIGD1 promotes migration, invasion, and
suppresses apoptosis of lung adenocarcinoma.
Lung Cancer. 2024;195:107918. PubMedAbstract available
LI Y, Xie F, Zheng Q, Zhang Y, et al Non-invasive diagnosis of pulmonary nodules by circulating tumor DNA methylation:
A prospective multicenter study.
Lung Cancer. 2024;195:107930. PubMedAbstract available
YING L, Lu T, Tian Y, Guo H, et al A predictive model for prognostic risk stratification of early-stage NSCLC based
on clinicopathological and miRNA panel.
Lung Cancer. 2024;195:107902. PubMedAbstract available
ALIREZAIE N, Chong AL, Kommoss FKF, Sabbaghian N, et al Exomic and epigenomic analysis of pulmonary blastoma.
Lung Cancer. 2024;195:107916. PubMedAbstract available
OTTE N, Fraune E, Cetiner Y, Felten MK, et al Asbestos Surveillance Program Aachen (ASPA): Cancer mortality among asbestos
exposed power industry workers.
Lung Cancer. 2024;195:107899. PubMedAbstract available
LU S, Zhang Y, Zhang G, Zhou J, et al Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or
metastatic NSCLC: Final overall survival results from a phase 2 trial.
Lung Cancer. 2024;195:107901. PubMedAbstract available
August 2024
GRIT GF, van Geffen E, Malmberg R, van Leeuwen R, et al Real-world overall survival after alternative dosing for pembrolizumab in the
treatment of non-small cell lung cancer: A nationwide retrospective cohort study
with a non-inferiority primary objective.
Lung Cancer. 2024;196:107950. PubMedAbstract available
LIAO D, Long M, Zhang J, Wei X, et al Efficacy and safety of pralsetinib in patients with RET fusion positive non-small
cell lung cancer: An observational real world study.
Lung Cancer. 2024;196:107936. PubMedAbstract available
FERREIRA M, Swalduz A, Greillier L, du Rusquec P, et al Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of
the IFCT-2104 CAPMATU study.
Lung Cancer. 2024;196:107934. PubMedAbstract available
MALHOTRA J, Chiappori A, Fujioka N, Hanna NH, et al Phase I/II trial of plinabulin in combination with nivolumab and ipilimumab in
patients with recurrent small cell lung cancer (SCLC): Big ten cancer research
consortium (BTCRC-LUN17-127) study.
Lung Cancer. 2024;195:107932. PubMedAbstract available
TASOUDIS P, Loufopoulos G, Manaki V, Doerr M, et al Long term outcomes after lobar versus sublobar resection for patients with
Non-Small cell lung Cancer: Systematic review and individual patient data
Meta-Analysis.
Lung Cancer. 2024;195:107929. PubMedAbstract available
BARSOUK A, Elghawy O, Heidlauf A, Yu C, et al Real-world outcomes of atypical EGFR-mutated metastatic non-small cell lung
cancer (mNSCLC)treated with osimertinib (osi) vs. Afatinib or erlotinib.
Lung Cancer. 2024;195:107926. PubMedAbstract available
RECK M, Dziadziuszko R, Sugawara S, Kao S, et al Five-year survival in patients with extensive-stage small cell lung cancer
treated with atezolizumab in the Phase III IMpower133 study and the Phase III
IMbrella A extension study.
Lung Cancer. 2024;196:107924. PubMedAbstract available
CALVO V, Niazmand E, Carcereny E, Rodriguez-Abreu D, et al Family history of cancer and lung cancer: Utility of big data and artificial
intelligence for exploring the role of genetic risk.
Lung Cancer. 2024;195:107920. PubMedAbstract available
DING Y, Lei S, Wang L, Tang L, et al Age-related efficacy of immunotherapies in advanced non-small cell lung cancer: a
comprehensive meta-analysis.
Lung Cancer. 2024;195:107925. PubMedAbstract available
TAMIYA A, Osuga M, Harada D, Isa SI, et al Mechanisms of resistance and correlation between pre-treatment co-alterations and
p-prognosis to osimertinib in chemo-naive advanced non-small cell lung cancer.
Lung Cancer. 2024;195:107917. PubMedAbstract available
BAUMAN JR, Liu G, Preeshagul I, Liu SV, et al Real-world treatment sequencing and effectiveness of second- and third-generation
ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung
cancer.
Lung Cancer. 2024;195:107919. PubMedAbstract available
GALLINA FT, Balzano V, Porciello N, Taje R, et al Trajectory of PD-L1 expression in a patient underwent neoadjuvant
chemo-immunotherapy for resectable NSCLC.
Lung Cancer. 2024;194:107900. PubMed
BARGHOUT SH, Zhan LJ, Raptis S, Al-Agha F, et al Treatment patterns and outcomes in KRAS(G12C)-positive advanced NSCLC patients
previously treated with immune checkpoint inhibitors: A Canada-wide real-world,
multi-center, retrospective cohort study.
Lung Cancer. 2024;194:107898. PubMedAbstract available
OYA Y, Imaizumi K, Mitsudomi T The next-generation KRAS inhibitors...What comes after sotorasib and adagrasib?
Lung Cancer. 2024;194:107886. PubMedAbstract available
WESPISER M, Swalduz A, Perol M Treatment sequences in EGFR mutant advanced NSCLC.
Lung Cancer. 2024;194:107895. PubMedAbstract available
WANG Q, Liu H, Xu Z, Zhang L, et al Effects of pregabalin combined with tramadol/paracetamol on acute pain in
patients with CT-guided puncture localization of pulmonary nodules.
Lung Cancer. 2024;194:107888. PubMedAbstract available
HUANG S, Cao C, Guo L, Li C, et al Comparison of the variability and diagnostic efficacy of respiratory-gated PET/CT
based radiomics features with ungated PET/CT in lung lesions.
Lung Cancer. 2024;194:107889. PubMedAbstract available
DOUMA LH, Baas P, de Gooijer CJ First-line doublet immunotherapy: Game changer or hype for patients with
mesothelioma?
Lung Cancer. 2024;194:107891. PubMed
XU Y, Zhang Y, Qiang H, Zhong H, et al Impact of PD-L1 expression on the efficacy of first-line crizotinib in advanced
ROS1-rearranged NSCLC.
Lung Cancer. 2024;194:107892. PubMedAbstract available
NIEDERMAIER B, Kou Y, Tong E, Eichinger M, et al CT-guided needle biopsy is not associated with increased ipsilateral pleural
metastasis.
Lung Cancer. 2024;194:107890. PubMedAbstract available
SPEEL EM, Dafni U, Thunnissen E, Hendrik Ruschoff J, et al ROS1 fusions in resected stage I-III adenocarcinoma: Results from the European
Thoracic Oncology Platform Lungscape project.
Lung Cancer. 2024;194:107860. PubMedAbstract available
KIM YJ, Kim S, Kim TM, Suh KJ, et al A phase II study of osimertinib in patients with NSCLC harboring EGFR exon 20
insertion: A multicenter trial of the Korean Cancer Study Group (LU17-19).
Lung Cancer. 2024;194:107870. PubMedAbstract available
BYLICKI O, Guisier F, Scherpereel A, Daniel C, et al Real-World efficacy and safety of combination nivolumab plus ipilimumab for
Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04-2021)
trial.
Lung Cancer. 2024;194:107866. PubMedAbstract available
OGAWA H, Koga T, Pham NA, Bernards N, et al Clinical and pathological predictors of engraftment for patient-derived
xenografts in lung adenocarcinoma.
Lung Cancer. 2024;194:107863. PubMedAbstract available
PROVENCIO M, Robado de Lope L, Serna-Blasco R, Nadal E, et al BRAF mutational status is associated with survival outcomes in locally advanced
resectable and metastatic NSCLC.
Lung Cancer. 2024;194:107865. PubMedAbstract available
ARRIETA O, Caballe-Perez E, Hernandez-Pedro N, Romero-Nunez E, et al Prevalence of pathogenic or likely pathogenic germline variants in cancer
predisposition genes among selected patients with lung adenocarcinoma: The
GERMLUNG study.
Lung Cancer. 2024;194:107864. PubMedAbstract available
July 2024
CASIRAGHI M, Cara A, Mazzella A, Girelli L, et al 1000 Robotic-assisted lobectomies for primary lung cancer: 16 years single center
experience.
Lung Cancer. 2024;195:107903. PubMedAbstract available
ZHENG Q, Lin X, Qi W, Yin J, et al NGS and FISH for MET amplification detection in EGFR TKI resistant non-small cell
lung cancer (NSCLC) patients: A prospective, multicenter study in China.
Lung Cancer. 2024;194:107897. PubMedAbstract available
FUJIMOTO D, Hayashi H, Murotani K, Toi Y, et al Prediction of prognosis in lung cancer using machine learning with
inter-institutional generalizability: A multicenter cohort study (WJOG15121L:
REAL-WIND).
Lung Cancer. 2024;194:107896. PubMedAbstract available
ASAO T, Shukuya T, Uemura K, Kitadai R, et al Risk and survival of patients with non-small cell lung cancer and pre-existing
autoimmune disorders receiving immune checkpoint blockade therapy: Survival
analysis with inverse probability weighting from a nationwide,
multi-institutional, retrospectiv
Lung Cancer. 2024;194:107894. PubMedAbstract available
BELLUOMINI L, Cesta Incani U, Smimmo A, Avancini A, et al Prognostic impact of Interleukin-8 levels in lung cancer: A meta-analysis and a
bioinformatic validation.
Lung Cancer. 2024;194:107893. PubMedAbstract available
JACOB M, Fournel P, Tissot C, Cadranel J, et al A prospective analysis of the management practices for patients with
Stage-III-N2Non-Small-Cell lung cancer (OBSERVE IIIA-B GFPC 04-2020Study).
Lung Cancer. 2024;194:107868. PubMedAbstract available
ZANDWIJK NV, Frank AL, Reid G, Dimitri Roe O, et al Asbestos-Related lung Cancer: An underappreciated oncological issue.
Lung Cancer. 2024;194:107861. PubMedAbstract available
PONS-TOSTIVINT E, Ezzedine R, Goronflot T, Crequit P, et al Second-line treatment outcomes after first-line chemotherapy plus immunotherapy
in Extensive-Stage small cell lung cancer (ES-SCLC) patients: A large French
multicenter study.
Lung Cancer. 2024;194:107887. PubMedAbstract available
IZUMI M, Costa DB, Kobayashi SS Targeting of drug-tolerant persister cells as an approach to counter drug
resistance in non-small cell lung cancer.
Lung Cancer. 2024;194:107885. PubMedAbstract available
LI R, Xu Y, Zhao J, Zhang L, et al Comparison of radiotherapy versus surgical resection following neoadjuvant
chemoimmunotherapy in potentially resectable stage III non-small-cell lung
cancer: A propensity score matching analysis.
Lung Cancer. 2024;194:107884. PubMedAbstract available
YOSHIZAKI C, Yoshida Y, Nohmi S, Go Y, et al EGFR-TKI-induced Factor V deficiency in a patient with advanced non-small cell
lung cancer: The first case report.
Lung Cancer. 2024;194:107869. PubMedAbstract available
DE BRUYCKER A, Schneiders F, Gulstene S, Moghanaki D, et al Evaluation of chest CT-scans following lung stereotactic ablative radiotherapy:
Challenges and new insights.
Lung Cancer. 2024;193:107848. PubMedAbstract available
SAW SPL, Low YF, Lai GGY, Chan LL, et al Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after
progression on first-line osimertinib in advanced EGFR-mutated NSCLC.
Lung Cancer. 2024;193:107856. PubMedAbstract available
ARMATO SG 3RD, Katz SI, Frauenfelder T, Jayasekera G, et al Imaging in pleural Mesothelioma: A review of the 16th International Conference of
the International Mesothelioma Interest Group.
Lung Cancer. 2024;193:107832. PubMedAbstract available
BORGHAEI H, Pundole X, Sangare L, Anderson E, et al Natural history of SCLC patients treated in third-line and beyond: A
retrospective real world study.
Lung Cancer. 2024;193:107819. PubMedAbstract available
FRANK AL, van Zandwijk N Asbestos history and use.
Lung Cancer. 2024;193:107828. PubMedAbstract available
ERNST SM, van Marion R, von der Thusen JH, Dubbink HJ, et al Exploring the use of circulating tumor DNA for mutational signature analysis.
Lung Cancer. 2024;193:107844. PubMed
June 2024
BLANCO-VILLAR ML, Exposito-Hernandez J, Navarro-Moreno E, Lopez Martin JM, et al Analyzing diagnostic and treatment wait times for lung cancer Patients: Key
insights from a provincial registry study.
Lung Cancer. 2024;194:107867. PubMedAbstract available
NISHIO M, Watanabe S, Udagawa H, Aragane N, et al Integrated analysis of older adults and patients with renal dysfunction in the
IMpower130 and IMpower132 randomized controlled trials for advanced non-squamous
non-small cell lung cancer.
Lung Cancer. 2024 Jun 28:107859. doi: 10.1016/j.lungcan.2024.107859. PubMedAbstract available
BUM LEE J, Huang Y, Oya Y, Nutzinger J, et al Modulating the gut microbiome in non-small cell lung cancer: Challenges and
opportunities.
Lung Cancer. 2024;194:107862. PubMedAbstract available
BEN-ARYE E, Gressel O, Lifshitz S, Peled N, et al Integrative oncology for patients with lung cancer: A prospective pragmatic
controlled trial.
Lung Cancer. 2024;193:107857. PubMedAbstract available
KLEBE S, Rathi V, Russell PA Lung cancer caused by asbestos: What a reporting pathologist needs to know.
Lung Cancer. 2024;195:107849. PubMedAbstract available
METINTAS M, Ak G, Metintas S Environmental asbestos exposure and lung cancer.
Lung Cancer. 2024;194:107850. PubMedAbstract available
ASANO Y, Yamamoto N, Demura S, Hayashi K, et al Combination therapy with immune checkpoint inhibitors and denosumab improves
clinical outcomes in non-small cell lung cancer with bone metastases.
Lung Cancer. 2024;193:107858. PubMedAbstract available
TAKEDA M, Shimokawa M, Nakamura A, Nosaki K, et al Corrigendum to "A phase II study (WJOG12819L) to assess the efficacy of
osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic
disease (T790M-negative) progressed after treatment with first- or
second-generation EGFR TKI and platin
Lung Cancer. 2024 Jun 17:107852. doi: 10.1016/j.lungcan.2024.107852. PubMed
CUPPENS K, Du Pont B, Knegjens J, Maes B, et al Immune checkpoint inhibition in early-stage non-small cell lung cancer.
Lung Cancer. 2024;193:107855. PubMedAbstract available
APTEKAR J, Jain R, Korytowsky B, Shafquat A, et al Brain metastases in clinical trial participants with KRAS-mutated advanced
non-small cell lung cancer receiving docetaxel: Pooled data analysis.
Lung Cancer. 2024;193:107854. PubMedAbstract available
ARRIETA O In response to "On the Hispanic paradox in lung cancer".
Lung Cancer. 2024;193:107853. PubMed
GAO X, Tan H, Zhu M, Zhang G, et al Construction and validation of a clinical differentiation model between
peripheral lung cancer and solitary pulmonary tuberculosis.
Lung Cancer. 2024;193:107851. PubMedAbstract available
MAHMOOD K, Wang H, Ji Z, Giovacchini CX, et al Differences in microenvironment of lung cancer and pleural effusions by
single-cell RNA sequencing.
Lung Cancer. 2024;193:107847. PubMedAbstract available
HUANG L, Petersen RH Impact of number of dissected lymph nodes on recurrence and survival following
thoracoscopic segmentectomy for clinical stage I non-small cell lung cancer.
Lung Cancer. 2024;193:107846. PubMedAbstract available
GOTO E, Taki T, Nomura K, Miyakami Y, et al Clinicopathological differences between EGFR mutated and EGFR wild-type lung
adenocarcinoma with papillary predominant pattern.
Lung Cancer. 2024;192:107830. PubMedAbstract available
LI M, Zhang Y, Zhou P, Miao Y, et al Mutational analysis of pulmonary large cell neuroendocrine carcinoma: APC gene
mutations identify a good prognostic factor.
Lung Cancer. 2024;192:107825. PubMedAbstract available
VORUGANTI MADDALI IS, Cunningham C, McLeod L, Bahig H, et al Optimal management of radiation pneumonitis: Findings of an international Delphi
consensus study.
Lung Cancer. 2024;192:107822. PubMedAbstract available
SHI M, Pang L, Zhou H, Mo S, et al Rare SMARCA4-deficient thoracic tumor: Insights into molecular characterization
and optimal therapeutics methods.
Lung Cancer. 2024;192:107818. PubMedAbstract available
SZENTKERESZTY M, Ladanyi A, Galffy G, Tovari J, et al Density of tumor-infiltrating NK and Treg cells is associated with 5 years
progression-free and overall survival in resected lung adenocarcinoma.
Lung Cancer. 2024;192:107824. PubMedAbstract available
CHEN Q, Xia L, Wang J, Zhu S, et al EGFR-mutant NSCLC may remodel TME from non-inflamed to inflamed through acquiring
resistance to EGFR-TKI treatment.
Lung Cancer. 2024;192:107815. PubMedAbstract available
SHAH R, Sun L, Ridge CA Image guided lung biopsy.
Lung Cancer. 2024;192:107803. PubMedAbstract available
MARTIN A, Carton M, Thery L, Burnod A, et al Palliative care integration and end-of-life care intensity for patients with
NSCLC.
Lung Cancer. 2024;192:107800. PubMedAbstract available
ISHIDOYA M, Makiguchi T, Tanaka H, Miura T, et al Endocrine immune-related adverse event is a prognostic biomarker independent of
lead-time bias.
Lung Cancer. 2024;192:107790. PubMedAbstract available
KLOTZ LV, Casjens S, Johnen G, Taeger D, et al Combination of calretinin, MALAT1, and GAS5 as a potential prognostic biomarker
to predict disease progression in surgically treated mesothelioma patients.
Lung Cancer. 2024;192:107802. PubMedAbstract available
May 2024
AMARI L, Tomasini P, Dantony E, Rousseau-Bussac G, et al Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or
without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with
EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted
therapies (GFPC
Lung Cancer. 2024;193:107843. PubMedAbstract available
PENG L, Lidan H, Cuicui Z, Zhe Z, et al DNA double-strand break repair capacity and its pathway gene variants predict the
risk and prognosis of lung cancer.
Lung Cancer. 2024;192:107831. PubMedAbstract available
KE H, Kao S, van Zandwijk N, Rasko JEJ, et al Circulating tumor cell detection may offer earlier diagnosis in patients
suspected of asbestos-related lung cancer.
Lung Cancer. 2024;192:107829. PubMedAbstract available
LUNDBERG FE, Ekman S, Johansson ALV, Engholm G, et al Trends in lung cancer survival in the Nordic countries 1990-2016: The NORDCAN
survival studies.
Lung Cancer. 2024;192:107826. PubMedAbstract available
HUANG Z, Zhang Y, Xu Q, Song L, et al Clinical treatment patterns, molecular characteristics and survival outcomes of
ROS1-rearranged non-small cell lung cancer: A large multicenter retrospective
study.
Lung Cancer. 2024;192:107827. PubMedAbstract available
LI Y, Wong M, Zhan L, Corke L, et al Single organ metastatic sites in non-small cell lung cancer: Patient
characteristics, treatment patterns and outcomes from a large retrospective
Canadian cohort.
Lung Cancer. 2024;192:107823. PubMedAbstract available
BARAMIDZE A, Makharadze T, Gogishvili M, Melkadze T, et al Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung
cancer with PD-L1 >/= 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2
trial.
Lung Cancer. 2024;193:107821. PubMedAbstract available
FELIP E, Metro G, Tan DSW, Wolf J, et al Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced
non-small cell lung cancer.
Lung Cancer. 2024;192:107820. PubMedAbstract available
NADAL E, Rifi N, Kane S, Mbacke S, et al Efficacy and safety of crizotinib in the treatment of advanced non-small cell
lung cancer with ROS1 gene fusion: a systematic literature review and
meta-analysis of real-world evidence.
Lung Cancer. 2024;192:107816. PubMedAbstract available
WANG Z, Li X, Chen J, Hua Y, et al The significance of inflammatory markers in prognosticating the effectiveness and
safety of immunotherapy in conjunction with chemotherapy during the primary
intervention of advanced non-small cell lung carcinoma.
Lung Cancer. 2024;192:107817. PubMedAbstract available
WANG L, Li L, Zhou X, Zhang D, et al Identification of a novel ALK inhibitor-sensitive PRKCE-ALK gene fusion in lung
adenocarcinoma.
Lung Cancer. 2024;191:107797. PubMed
LU YF, Chang YH, Chen YJ, Hsieh MS, et al Proteomic profiling of tumor microenvironment and prognosis risk prediction in
stage I lung adenocarcinoma.
Lung Cancer. 2024;191:107791. PubMedAbstract available
CHOUR A, Basse C, Lebosse F, Bonte PE, et al Management of sotorasib-related adverse events and hepatotoxicities following
anti-PD-(L)1 therapy: Experience with sotorasib in two French anti-cancer centers
and practical guidance proposal.
Lung Cancer. 2024;191:107789. PubMedAbstract available
MIYAKOSHI J, Yoshida T, Kashima J, Shirasawa M, et al Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the
efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expression.
Lung Cancer. 2024;191:107788. PubMedAbstract available
NISHIMURA T, Fujimoto H Is the onset of immune-related adverse events themselves a prognostic factor or a
confounding factor?
Lung Cancer. 2024;191:107561. PubMed
HOCKING AJ, Mortimer LA, Farrall AL, Russell PA, et al Establishing mesothelioma patient-derived organoid models from malignant pleural
effusions.
Lung Cancer. 2024;191:107542. PubMedAbstract available
LIU G, Mazieres J, Stratmann J, Ou SI, et al A pragmatic guide for management of adverse events associated with lorlatinib.
Lung Cancer. 2024;191:107535. PubMedAbstract available
April 2024
OKAHISA M, Udagawa H, Matsumoto S, Kato T, et al Clinical outcomes in patients with non-small cell lung cancer harboring EGFR
Exon20 in-frame insertions in the near-loop and far-loop: Results from
LC-SCRUM-Asia.
Lung Cancer. 2024;191:107798. PubMedAbstract available
ZHANG SL, Tian Y, Yu J, Zhang JH, et al Is neoadjuvant immunotherapy necessary in patients with programmed death ligand 1
expression-negative resectable non-small cell lung cancer? A systematic review
and meta-analysis.
Lung Cancer. 2024;191:107799. PubMedAbstract available
BADE BC, Zhao J, Li F, Tanoue L, et al Trends and predictors of Quality of Life in lung cancer survivors.
Lung Cancer. 2024;191:107793. PubMedAbstract available
LIU S, Graves N, Tan AC The cost-effectiveness of including liquid biopsy into molecular profiling
strategies for newly diagnosed advanced non-squamous non-small cell lung cancer
in an Asian population.
Lung Cancer. 2024;191:107794. PubMedAbstract available
DE RUITER JC, van der Noort V, van Diessen JNA, Smit EF, et al The optimal treatment for patients with stage I non-small cell lung cancer:
minimally invasive lobectomy versus stereotactic ablative radiotherapy - a
nationwide cohort study.
Lung Cancer. 2024;191:107792. PubMedAbstract available
MALAPELLE U, Passiglia F, Pepe F, Pisapia P, et al The biomarkers ATLAS: An audit on 1100 non-small cell lung cancer from an Italian
knowledge-based database.
Lung Cancer. 2024;191:107787. PubMedAbstract available
TAVERNA JA, Hung CN, Williams M, Williams R, et al Ex vivo drug testing of patient-derived lung organoids to predict treatment
responses for personalized medicine.
Lung Cancer. 2024;190:107533. PubMedAbstract available
JUNG HA, Park B, Park S, Sun JM, et al Survival benefit in EGFR-wild and ALK negative NSCLC patients who participate in
clinical trials compared to standard-of-care: Propensity-matched analysis.
Lung Cancer. 2024;190:107536. PubMedAbstract available
YU T, Zhou X, Li M Comment on: Frozen sections accurately predict the IASLC proposed grading system
and prognosis in patients with invasive lung adenocarcinomas.
Lung Cancer. 2024;190:107534. PubMed
PANG LL, Zhuang WT, Huang YH, Liao J, et al Uncommon de novo EGFR(T790M)-Mutant NSCLC characterized with unique genetic
Features: Clinical response and acquired resistance to the third-generation
EGFR-TKIs treatment.
Lung Cancer. 2024;190:107528. PubMedAbstract available
DAMHUIS RAM, Dickhoff C, Bahce I, Senan S, et al Population-based survival rates after curative surgical and non-surgical
treatment of stage III NSCLC since 2017.
Lung Cancer. 2024;190:107532. PubMedAbstract available
SLATORE CG, Hooker ER, Shull S, Golden SE, et al Association of patient and health care organization factors with incidental
nodule guidelines adherence: A multi-system observational study.
Lung Cancer. 2024;190:107526. PubMedAbstract available
SUN L, Handorf EA, Zhou Y, Borghaei H, et al Outcomes in patients treated with frontline immune checkpoint inhibition (ICI)
for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1
levels.
Lung Cancer. 2024;190:107510. PubMedAbstract available
PROVENCIO M, Cobo M, Rodriguez-Abreu D, Carcereny E, et al Describing differences among populations of thoracic tumors patients under and
over 80 years: Data analysis from the SLCG thoracic tumor registry.
Lung Cancer. 2024;190:107513. PubMedAbstract available
HONG DS, Cappuzzo F, Chul Cho B, Dowlati A, et al Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in
patients with advanced NSCLC containing MET activating alterations.
Lung Cancer. 2024;190:107512. PubMedAbstract available
March 2024
GABRIEL L, McVeigh T, Macmahon S, Avila Z, et al Familial rare EGFR-mutant lung cancer syndrome: Review of literature and
description of R776H family.
Lung Cancer. 2024;191:107543. PubMedAbstract available
LYHNE CHRISTENSEN N, Gouliaev A, McPhail S, Lyratzopoulos G, et al Lung cancer among the Elderly in Denmark - A comprehensive population-based
cohort study.
Lung Cancer. 2024;191:107555. PubMedAbstract available
SUN M, Feng Q, Yan Q, Zhao H, et al Malate, a natural inhibitor of 6PGD, improves the efficacy of chemotherapy in
lung cancer.
Lung Cancer. 2024;190:107541. PubMedAbstract available
TOZUKA T, Noro R, Mizutani H, Kurimoto F, et al Osimertinib plus local treatment for brain metastases versus osimertinib alone in
patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Lung Cancer. 2024;191:107540. PubMedAbstract available
RODRIGUEZ J On the Hispanic paradox in lung cancer.
Lung Cancer. 2024;190:107537. PubMed
GUDINA AT, Kamen C, Hardy SJ, Kehoe L, et al Revisiting the lung cancer screening eligibility criteria to promote equity for
Black individuals.
Lung Cancer. 2024;191:107539. PubMedAbstract available
PU X, Xiao Z, Li J, Wu Z, et al Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung
cancer patients who failed first-line treatment: A multicenter, randomized phase
II trial.
Lung Cancer. 2024;191:107538. PubMedAbstract available
WALLACE ND, Alexander M, Xie J, Ball D, et al The impact of pre-treatment smoking status on survival after chemoradiotherapy
for locally advanced non-small-cell lung cancer.
Lung Cancer. 2024;190:107531. PubMedAbstract available
KIM DW, Chul Cho B, Pachipala K, Kim SW, et al Durvalumab in combination with chemoradiotherapy for patients with unresectable
stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study.
Lung Cancer. 2024;190:107530. PubMedAbstract available
CONNOR WELLS J, Mullin MM, Ho C, Melosky B, et al Outcomes of patients with advanced epithelial growth factor receptor mutant lung
cancer treated with first-line osimertinib who would not have met the eligibility
criteria for the FLAURA clinical trial.
Lung Cancer. 2024;190:107529. PubMedAbstract available
KRAUS KM, Oreshko M, Schnabel JA, Bernhardt D, et al Dosiomics and radiomics-based prediction of pneumonitis after radiotherapy and
immune checkpoint inhibition: The relevance of fractionation.
Lung Cancer. 2024;189:107507. PubMedAbstract available
KAIRA K, Imai H, Kagamu H Drastic response of sunitinib after failure of Lenvatinib in patients with
previously treated thymic carcinoma.
Lung Cancer. 2024;189:107501. PubMed
ZHOU P, Fu Y, Tang Y, Jiang L, et al Thoracic SMARCA4-deficient undifferentiated tumor: A clinicopathological and
prognostic analysis of 35 cases and immunotherapy efficacy.
Lung Cancer. 2024;189:107471. PubMedAbstract available
MOLINA TJ, Roden AC, Szolkowska M, Shimizu S, et al International reproducibility study of thymic epithelial tumors staging: pT stage
is an issue. proposals for improvement. A RYTHMIC/ITMIG study.
Lung Cancer. 2024;189:107479. PubMedAbstract available
KLOKER LD, Sidiras M, Flaadt T, Brecht IB, et al Clinical management of NUT carcinoma (NC) in Germany: Analysis of survival,
therapy response, tumor markers and tumor genome sequencing in 35 adult patients.
Lung Cancer. 2024;189:107496. PubMedAbstract available
FITZGERALD SM Resolving asbestos and ultrafine particulate definitions with carcinogenicity.
Lung Cancer. 2024;189:107478. PubMedAbstract available
STARES M, Doyle E, Chapple S, Raynes G, et al Prognostic value of the Scottish Inflammatory prognostic Score in patients with
NSCLC expressing PD-L1 >/= 50 % progressing on first-line pembrolizumab.
Lung Cancer. 2024;189:107497. PubMedAbstract available
CHEN Y, Chen H, Yu R, Zeng X, et al Pulmonary blastoma is successfully treated with immunotherapy and targeted
therapy.
Lung Cancer. 2024;189:107476. PubMedAbstract available
February 2024
GOULIAEV A, Ali F, Jakobsen E, Dalton SO, et al The Danish lung cancer registry: A nationwide validation study.
Lung Cancer. 2024;190:107527. PubMedAbstract available
LEE JD, Zheng R, Okusanya OT, Evans NR 3rd, et al Association between surgical quality and long-term survival in lung cancer.
Lung Cancer. 2024;190:107511. PubMedAbstract available
SAEKI Y, Maki N, Nemoto T, Inada K, et al Lung cancer detection in perioperative patients' exhaled breath with
nanomechanical sensor array.
Lung Cancer. 2024;190:107514. PubMedAbstract available
CHUL CHO B, Han JY, Hyeong Lee K, Lee YG, et al Lazertinib as a frontline treatment in patients with EGFR-mutated advanced
non-small cell lung cancer: Long-term follow-up results from LASER201.
Lung Cancer. 2024;190:107509. PubMedAbstract available
BAPTISTE OUDART J, Garinet S, Leger C, Barlesi F, et al STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage
non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT
TASTE trial.
Lung Cancer. 2024;190:107508. PubMedAbstract available
BAR J, Esteban E, Rodriguez-Abreu D, Aix SP, et al Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in
non-small cell lung cancer: KEYNOTE-782.
Lung Cancer. 2024;190:107506. PubMedAbstract available
SAAL J, Bald T, Eckstein M, Ralser DJ, et al Integration of on-treatment modified Glasgow prognostic score (mGPS) to improve
imaging-based prediction of outcomes in patients with non-small cell lung cancer
on immune checkpoint inhibition.
Lung Cancer. 2024;189:107505. PubMedAbstract available
LAESEKE P, Ng C, Naghi A, Wright GWJ, et al Response to letter: Microwave ablation for Early-Stage Non-Small cell Lung
Cancer: Don't Put the Cart before the stereotactic Horse.
Lung Cancer. 2024;189:107504. PubMed
WANG S, Hao X, Dai L, Lou N, et al Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer
receiving ALK-TKIs therapy.
Lung Cancer. 2024;189:107503. PubMedAbstract available
SAIGI M, Mate JL, Carcereny E, Martinez-Cardus A, et al HLA-I levels correlate with survival outcomes in response to immune checkpoint
inhibitors in non-small cell lung cancer.
Lung Cancer. 2024;189:107502. PubMedAbstract available
KUNIMASA K, Tamiya M, Inoue T, Kawamura T, et al Clinical application of the Lung Cancer Compact Panel(TM) using various types of
cytological specimens in patients with lung cancer.
Lung Cancer. 2024;189:107498. PubMedAbstract available
LIU SV, Frohn C, Minasi L, Fernamberg K, et al Real-world outcomes associated with afatinib use in patients with solid tumors
harboring NRG1 gene fusions.
Lung Cancer. 2024;188:107469. PubMedAbstract available
ZHANG YH, Liu XS, Gao Y, Yuan LL, et al SFXN1 as a potential diagnostic and prognostic biomarker of LUAD is associated
with (18)F-FDG metabolic parameters.
Lung Cancer. 2024;188:107449. PubMedAbstract available
KITAGAWA S, Zenke Y, Taki T, Aokage K, et al Prognostic value of predominant subtype in pathological stage II-III lung
adenocarcinoma with epidermal growth factor receptor mutation.
Lung Cancer. 2024;188:107453. PubMedAbstract available
BURNS L, Tukachinsky H, Raskina K, Huang RSP, et al Real-World comprehensive genomic profiling data for diagnostic clarity in
pulmonary Large-Cell neuroendocrine carcinoma.
Lung Cancer. 2024;188:107454. PubMedAbstract available
January 2024
WANG Y, Hu C, Yu H, Hu J, et al Insensitivity of oncogenic EGFR R776L mutation to EGFR inhibitors in lung cancer.
Lung Cancer. 2024;189:107495. PubMedAbstract available
HUANG S, Zhao M, Li S, Chen T, et al Incorporation of the lepidic component as an additional pathological T descriptor
for non-small cell lung cancer: Data from 3335 cases of lung adenocarcinoma.
Lung Cancer. 2024;189:107472. PubMedAbstract available
GENET SAAM, Visser E, Youssef-El Soud M, Belderbos HNA, et al Strengths and challenges in current lung cancer care: Timeliness and diagnostic
procedures in six Dutch hospitals.
Lung Cancer. 2024;189:107477. PubMedAbstract available
WU H, Zhang Q, Zhai W, Chen Y, et al Effectiveness of high-dose third-generation EGFR-tyrosine kinase inhibitors in
treating EGFR-mutated non-small cell lung cancer patients with leptomeningeal
metastasis.
Lung Cancer. 2024;188:107475. PubMedAbstract available
VAN ZANDWIJK N, Frank AL A multidisciplinary review of several aspects of Asbestos-Related Lung Cancer
(ARLC).
Lung Cancer. 2024 Jan 17:107474. doi: 10.1016/j.lungcan.2024.107474. PubMed
PAZ-ARES L, Goto Y, Wan-Teck Lim D, Halmos B, et al Canakinumab in combination with docetaxel compared with docetaxel alone for the
treatment of advanced non-small cell lung cancer following platinum-based doublet
chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized,
double-blind, phase
Lung Cancer. 2024;189:107451. PubMedAbstract available
NORITAKE O, Nakamura S, Kinoshita F, Aokage K, et al Prognostic impact of adjuvant therapy for cisplatin-unfit patients with
non-small-cell lung cancer: A multicenter analysis.
Lung Cancer. 2024;188:107470. PubMedAbstract available
CHIANG CL, Huang HC, Luo YH, Shen CI, et al Clinical utility of immunohistochemical subtyping in patients with small cell
lung cancer.
Lung Cancer. 2024;188:107473. PubMedAbstract available
ZHAO S, Ma Y, Liu L, Fang J, et al Ningetinib plus gefitinib in EGFR-mutant non-small-cell lung cancer with MET and
AXL dysregulations: A phase 1b clinical trial and biomarker analysis.
Lung Cancer. 2024;188:107468. PubMedAbstract available
PASSIGLIA F, Lucia Reale M, Lo Russo G, Pasello G, et al Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian
expanded access program.
Lung Cancer. 2024;187:107444. PubMedAbstract available
MIKUBO M, Tamagawa S, Kondo Y, Hayashi S, et al Micropapillary and solid components as high-grade patterns in IASLC grading
system of lung adenocarcinoma: Clinical implications and management.
Lung Cancer. 2024;187:107445. PubMedAbstract available
GAO J, Ao Y, Wang S, Chen Z, et al WHO histological classification and tumor size are predictors of the locally
aggressive behavior of thymic epithelial tumors.
Lung Cancer. 2024;187:107446. PubMedAbstract available
GAO L, Ai X, Lu S ETV6::NTRK3 gene fusion in a patient with metastatic lung atypical carcinoid
successfully treated with repotrectinib: A case report.
Lung Cancer. 2024;187:107443. PubMedAbstract available
DUMOULIN DW, Douma LH, Hofman MM, van der Noort V, et al Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma.
Lung Cancer. 2024;187:107440. PubMedAbstract available
LEBOUILLE-VELDMAN AB, Taros TN, Nawabi NLA, Mekary RA, et al Brief report on the efficacy of sotorasib in KRAS-Mutated NSCLC patients with
brain metastases.
Lung Cancer. 2024;187:107425. PubMedAbstract available
December 2023
CHENG Y, Wu L, Huang D, Wang Q, et al Myeloprotection with trilaciclib in Chinese patients with extensive-stage small
cell lung cancer receiving chemotherapy: Results from a randomized, double-blind,
placebo-controlled phase III study (TRACES).
Lung Cancer. 2023;188:107455. PubMedAbstract available
SAKATA Y, Saito G, Sakata S, Oya Y, et al Corrigendum to "Osimertinib as first-line treatment for elderly patients with
advanced EGFR mutation-positive non-small-cell lung cancer in a real-world
setting (OSI-FACT-EP)" [Lung Cancer 186 (2023) 107426].
Lung Cancer. 2023 Dec 29:107450. doi: 10.1016/j.lungcan.2023.107450. PubMed
PETERS S, Trigo J, Besse B, Moreno V, et al Lurbinectedin in patients with small cell lung cancer with chemotherapy-free
interval >/=30 days and without central nervous metastases.
Lung Cancer. 2023;188:107448. PubMedAbstract available
TAKAM KAMGA P, Mayenga M, Sebane L, Costantini A, et al Colony stimulating factor-1 (CSF-1) signalling is predictive of response to
immune checkpoint inhibitors in advanced non-small cell lung cancer.
Lung Cancer. 2023;188:107447. PubMedAbstract available
STUART CM, Dyas AR, Bronsert MR, Velopulos CG, et al The Effect of Social Vulnerability on Initial Stage and Treatment for Non-Small
Cell Lung Cancer.
Lung Cancer. 2023;188:107452. PubMedAbstract available
GRIDELLI C, Peters S, Mok T, Garassino M, et al Face to face among different chemo-immunotherapy combinations in the first line
treatment of patients with advanced non-small cell lung cancer: Results of an
international expert panel meeting by the italian association of thoracic
oncology (AIOT).
Lung Cancer. 2023;187:107441. PubMedAbstract available
CHO BC, Chiu CH, Massarelli E, Buchschacher GL, et al Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell
lung cancer.
Lung Cancer. 2023;188:107442. PubMedAbstract available
WANG L, Diao M, Zhang Z, Jiang M, et al Comparison of the somatic genomic landscape between central- and peripheral-type
non-small cell lung cancer.
Lung Cancer. 2023;187:107439. PubMedAbstract available
CAVAZZONI A, Digiacomo G, Volta F, Alfieri R, et al PD-L1 overexpression induces STAT signaling and promotes the secretion of
pro-angiogenic cytokines in non-small cell lung cancer (NSCLC).
Lung Cancer. 2023;187:107438. PubMedAbstract available
NASH J, Brims F International standards of care in thoracic oncology: A narrative review of
clinical quality indicators.
Lung Cancer. 2023;186:107421. PubMedAbstract available
AKRAM F, Wolf JL, Trandafir TE, Dingemans AC, et al Artificial intelligence-based recurrence prediction outperforms classical
histopathological methods in pulmonary adenocarcinoma biopsies.
Lung Cancer. 2023;186:107413. PubMedAbstract available
LIU Z, Wu Q, Li W, Li P, et al A novel intergenic (between REG3A and CTNNA2-AS1)-ALK fusion responds to
alectinib in lung adenocarcinoma.
Lung Cancer. 2023;186:107386. PubMedAbstract available
LINGLING X, Maoxi C, Wei Y, Jieting Z, et al Transformation of NSCLC to SCLC harboring EML4-ALK fusion with V1180L mutation
after alectinib resistance and response to lorlatinib: A case report and
literature review.
Lung Cancer. 2023;186:107415. PubMedAbstract available
SCHMALZ L, Bloomer C, Zhang W, Petty W, et al Durable response to amivantamab in treatment refractory NSCLC harboring EGFR and
complex MET mutations: A case report.
Lung Cancer. 2023;186:107400. PubMedAbstract available
YIN X, Li J, Chen B, Liu K, et al The predictive value of (18)F-FDG PET/CT combined with inflammatory index for
major pathological reactions in resectable NSCLC receiving neoadjuvant
immunochemotherapy.
Lung Cancer. 2023;186:107389. PubMedAbstract available
SUN J, Zhang L, Hu B, Du Z, et al Deep learning-based solid component measuring enabled interpretable prediction of
tumor invasiveness for lung adenocarcinoma.
Lung Cancer. 2023;186:107392. PubMedAbstract available
November 2023
SCHULER A, Huser J, Schmid S, Schar S, et al Patterns of progression on first line osimertinib in patients with EGFR
mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort
study.
Lung Cancer. 2023;187:107427. PubMedAbstract available
SAKATA Y, Saito G, Sakata S, Oya Y, et al Osimertinib as first-line treatment for elderly patients with advanced EGFR
mutation-positive non-small cell lung cancer in a real-world setting
(OSI-FACT-EP).
Lung Cancer. 2023;186:107426. PubMedAbstract available
LIVANOU ME, Syrigos NK, Montgomery A, Moeckel C, et al Eligibility for screening with low-dose CT in a real-world cohort of patients
with lung cancer in Greece: A brief report.
Lung Cancer. 2023;186:107424. PubMedAbstract available
GARON EB, Cho BC, Luft A, Alatorre-Alexander J, et al Patient-reported outcomes with durvalumab, with or without tremelimumab, plus
chemotherapy as first-line treatment for metastatic non-small-cell lung cancer
(POSEIDON).
Lung Cancer. 2023;186:107422. PubMedAbstract available
KOCHER WULFECK M, Plesner S, Herndon JE 2nd, Christensen JD, et al Characterizing Lung-RADS category 4 lesions in a university lung cancer screening
program.
Lung Cancer. 2023;186:107420. PubMedAbstract available
MAJEM M, Basch E, Cella D, Garon EB, et al Understanding health-related quality of life measures used in early-stage
non-small cell lung cancer clinical trials: A review.
Lung Cancer. 2023;187:107419. PubMedAbstract available
KATO T, Casarini I, Cobo M, Faivre-Finn C, et al Targeted treatment for unresectable EGFR mutation-positive stage III non-small
cell lung cancer: Emerging evidence and future perspectives.
Lung Cancer. 2023;187:107414. PubMedAbstract available
October 2023
LIU SV, Mok TSK, Nabet BY, Mansfield AS, et al Clinical and molecular characterization of long-term survivors with
extensive-stage small cell lung cancer treated with first-line atezolizumab plus
carboplatin and etoposide.
Lung Cancer. 2023;186:107418. PubMedAbstract available
MANGLAVITI S, Bini M, Apollonio G, Zecca E, et al High bone tumor burden to identify advanced non-small cell lung cancer patients
with survival benefit upon bone targeted agents and immune checkpoint inhibitors.
Lung Cancer. 2023;186:107417. PubMedAbstract available
FURUNE S, Ando Y Comment on: Carboplatin and irinotecan (CI) vs. Carboplatin and etoposide (CE)
for the treatment of extended-stage small-cell lung cancer in an elderly
population: A phase II/III randomized control trial.
Lung Cancer. 2023;186:107416. PubMed
KIM W, Lee SC, Lee WR, Chun S, et al The effect of the introduction of the national lung cancer screening program on
short-term mortality in Korea.
Lung Cancer. 2023;186:107412. PubMedAbstract available
HUANG S, Wu J, Li S, Li X, et al Evaluation of combined pathological responses in primary tumor and lymph nodes
following neoadjuvant chemoimmunotherapy in non-small cell lung cancer.
Lung Cancer. 2023;186:107401. PubMedAbstract available
DEHEM A, Mazieres J, Chour A, Guisier F, et al Characterization of 164 patients with NRAS mutated non-small cell lung cancer
(NSCLC).
Lung Cancer. 2023;186:107393. PubMedAbstract available
MORETTI A, Kovacevic B, Vilmann P, Annema JT, et al Performance of EUS-FNA and EUS-B-FNA for the diagnosis of left adrenal glands
metastases in patients with lung cancer: A systematic review and meta-analysis.
Lung Cancer. 2023;186:107391. PubMedAbstract available
RYU WK, Yong SH, Lee SH, Gwon HR, et al Usefulness of bronchial washing fluid for detection of EGFR mutations in
non-small cell lung cancer.
Lung Cancer. 2023;186:107390. PubMedAbstract available
RUGGIRELLO M, Valsecchi C, Ledda RE, Sabia F, et al Long-term outcomes of lung cancer screening in males and females.
Lung Cancer. 2023;185:107387. PubMedAbstract available
LIM TKH, Skoulidis F, Kerr KM, Ahn MJ, et al KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing.
Lung Cancer. 2023;184:107293. PubMedAbstract available
HO H, Yu SL, Chen HY, Yuan SS, et al Whole exome sequencing and MicroRNA profiling of lung adenocarcinoma identified
risk prediction features for tumors at stage I and its substages.
Lung Cancer. 2023;184:107352. PubMedAbstract available
MATSUNAGA T, Suzuki K, Hattori A, Fukui M, et al A problem with clinical T factor in the 8th TNM edition: Prognosis and EGFR
mutation status of small sized lung cancers with difficulty to measure the
diameter of solid component in part-solid tumor.
Lung Cancer. 2023;184:107354. PubMedAbstract available
LINDBERG K Balancing tumour control probability and toxicity in SBRT of ultra-central lung
tumours - One step forward.
Lung Cancer. 2023;184:107343. PubMed
GOTO E, Takamochi K, Kishikawa S, Hayashi T, et al Stepwise progression of invasive mucinous adenocarcinoma based on radiological
and biological characteristics.
Lung Cancer. 2023;184:107348. PubMedAbstract available
QI R, Fu X, Yu Y, Xu H, et al Efficacy and safety of re-challenging 160 mg furmonertinib for advanced NSCLC
after resistance to third-generation EGFR-TKIs targeted agents: A real-world
study.
Lung Cancer. 2023;184:107346. PubMedAbstract available
SEKER-CIN H, Tay TKY, Kazdal D, Kluck K, et al Analysis of rare fusions in NSCLC: Genomic architecture and clinical
implications.
Lung Cancer. 2023;184:107317. PubMedAbstract available
ZIRANU P, Ferrari PA, Guerrera F, Bertoglio P, et al Clinical score for colorectal cancer patients with lung-limited metastases
undergoing surgical resection: Meta-Lung Score.
Lung Cancer. 2023;184:107342. PubMedAbstract available
YEUNG V, Zaemes J, Yeh J, Giancarlo C, et al High levels of expression of Trop-2 in thymic epithelial tumors.
Lung Cancer. 2023;184:107324. PubMedAbstract available
GEMINE RE, Davies GR, Lanyon K, Rees SE, et al Quitting smoking improves two-year survival after a diagnosis of non-small cell
lung cancer.
Lung Cancer. 2023;186:107388. PubMedAbstract available
September 2023
NUTZINGER J, Bum Lee J, Li Low J, Ling Chia P, et al Management of HER2 alterations in non-small cell lung cancer - The past, present,
and future.
Lung Cancer. 2023;186:107385. PubMedAbstract available
CHOW R, McMillan MT, Simone CB 2nd Microwave Ablation for Early-Stage Non-Small Cell Lung Cancer: Don't Put the Cart
Before the Stereotactic Horse.
Lung Cancer. 2023;185:107382. PubMed
ZHANG Y, Li N, Dong Y, Wang W, et al Spatial microenvironment heterogeneity in therapy-naive lung cancer: A concept
with more attention needed.
Lung Cancer. 2023;185:107384. PubMed
DAGOGO-JACK I, Kiedrowski LA, Lennerz JK Molecular heterogeneity and co-altered genes in MET-amplified ALK-positive lung
cancer: Implications for MET targeted therapy.
Lung Cancer. 2023;186:107383. PubMedAbstract available
FALCHERO L, Guisier F, Darrason M, Boyer A, et al Long-term effectiveness and treatment sequences in patients with extensive stage
small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the
IFCT-1905 CLINATEZO real-world study.
Lung Cancer. 2023;185:107379. PubMedAbstract available
KRAMER T, Kuijvenhoven JC, von der Thusen J, Cohen D, et al Endobronchial ultrasound in diagnosing and staging of lung cancer by Acquire 22G
TBNB versus regular 22G TBNA needles: A randomized clinical trial.
Lung Cancer. 2023;185:107362. PubMedAbstract available
PARRA-MEDINA R, Pablo Castaneda-Gonzalez J, Montoya L, Paula Gomez-Gomez M, et al Prevalence of oncogenic driver mutations in Hispanics/Latin patients with lung
cancer. A systematic review and meta-analysis.
Lung Cancer. 2023;185:107378. PubMedAbstract available
GARCIA CAMPELO MR, Wan Y, Lin HM, Chen T, et al Q-TWiST analysis of survival benefits with brigatinib versus crizotinib in
patients with anaplastic lymphoma kinase-positive non-small cell lung cancer
based on results of the ALTA-1L trial.
Lung Cancer. 2023;185:107376. PubMedAbstract available
BOESCHEN M, Kuhn CK, Wirtz H, Seyfarth HJ, et al Comparative bioinformatic analysis of KRAS, STK11 and KEAP1 (co-)mutations in
non-small cell lung cancer with a special focus on KRAS G12C.
Lung Cancer. 2023;184:107361. PubMedAbstract available
PORTA C, Pradelli L, Sicari E, Castellani S, et al Liquid biopsy comprehensive genomic profiling of lung cancer in the Italian
population: A real-world experience.
Lung Cancer. 2023;185:107359. PubMedAbstract available
HAN D, Zhu Y, Choudhry AA, Cheng J, et al Association of telomere length with risk of lung cancer: A large prospective
cohort study from the UK Biobank.
Lung Cancer. 2023;184:107358. PubMedAbstract available
August 2023
ZHAO Y, Ma Y, Fan Y, Zhou J, et al A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4
bispecific antibody) monotherapy in previously treated advanced non-small-cell
lung cancer (AK104-202 study).
Lung Cancer. 2023;184:107355. PubMedAbstract available
KU HY, Lin SM, Wang CL, Lo YC, et al Impact of pathological nodal staging and tumour differentiation on survival and
postoperative radiotherapy in completely resected stage IIIA Non-small-cell lung
cancer.
Lung Cancer. 2023;184:107357. PubMedAbstract available
ZENG L, Zhou Y, Xu Q, Huang Z, et al Dynamic cytokines signature predicts survival outcome from severe Immune-related
hepatitis with PD-1/PD-L1 blockade in lung cancer.
Lung Cancer. 2023;184:107350. PubMedAbstract available
LEFEBVRE AM, Adam J, Nicolazzi C, Larois C, et al The search for therapeutic targets in lung cancer: Preclinical and human studies
of carcinoembryonic antigen-related cell adhesion molecule 5 expression and its
associated molecular landscape.
Lung Cancer. 2023;184:107356. PubMedAbstract available
BOZORGMEHR F, Muller A, Rawluk J, Sianidou M, et al Immune checkpoint inhibitors in non-small cell lung cancer - When should we dare
to stop treatment?
Lung Cancer. 2023;184:107340. PubMedAbstract available
LEVALLET G, Dubois F, Elie N, Creveuil C, et al VEGFR2 and CD34 expression associated with longer survival in patients with
pleural mesothelioma in the IFCT-GFPC-0701 MAPS phase 3 trial.
Lung Cancer. 2023;182:107287. PubMedAbstract available